In addition, studies in animal models have also shown that adoptive therapy with CD4+ and/or CD8+ T cells can efficiently control respiratory infections including SARS-CoV-1, MERS, and influenza viruses (54–56). Here, CD8A is linked to respiratory tract infectious disorder.